← All trials
NCT06204419
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 26, 2023
- Primary completion
- Jul 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- Jan 12, 2024
- Last posted
- Jan 12, 2024
- Enrollment
- 86
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Infinity Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.